News

12.22.2015

Sylvester to Become First Ablatherm Robotic HIFU Site in Eastern United States

Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, will become the first location in the Eastern United States to be equipped with the Ablatherm robotic high-intensity focused ultrasound (HIFU) device, which is used for prostate tissue removal.

“We are pleased to add Ablatherm Robotic HIFU to our range of prostate ablation tools, as it complements our existing strength in robotic surgery,” said Dipen J. Parekh, M.D., a robotic surgeon and urologic oncologist at Sylvester.

“With the recent FDA clearance of HIFU for prostate tissue ablation, this is an exciting time for the urology community and an opportunity to make a meaningful difference in the lives of prostate cancer patients,” said Parekh, who is also professor and Chair of the Department of Urology and Director of Robotic Surgery at the University of Miami Miller School of Medicine. “This is a truly non-invasive technique with the potential of significantly reduced side effects related to surgery and radiation. We look forward to working with EDAP to bring the system online and initiating patient treatments.”

The Ablatherm Robotic HIFU device, manufactured by EDAP TMS, a French company, is used outside of the U.S. for the treatment of prostate cancer.

“We are excited to have Sylvester and the University of Miami’s Department of Urology among the first academic users of Ablatherm Robotic HIFU in the U.S.,” said Marc Oczachowski, CEO of EDAP TMS. “This sale is extremely important in our U.S. expansion strategy, which is focused on collaborating with leading academic and scientific centers to further establish the technology and accelerate its clinical recognition. We are honored to be working with such a respected robotic surgeon, urologist and Gold Cystoscope winner as Dr. Dipen Parekh and are looking forward to supporting him and his team.”

Ablatherm-HIFU is used for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment.

News Archives

Office of the Dean

A message from the dean

Physician News

Read Med News

e-Update

Read e-Update